Resources
31 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 7/13/2020 (updated 3/28/2024)
The Facts About Buprenorphine for Treatment of Opioid Addiction is available in many languages, including Spanish.
Posted 10/23/2020 (updated 4/3/2024)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 12/16/2020 (updated 4/4/2024)
As states seek new tools to meet the needs of individuals with substance use disorder (SUD) and opioid use disorder, federally qualified health centers (FQHCs) offer unique resources and examples for developing integrated and cost-effective health care services for complex and chronic conditions. The National Academy for State Health Policy developed this toolkit to share innovations, resources, and lessons learned from five state teams (AL, IL, SD, VA, and WI) that are working to strengthen the capacity of their FQHCs to deliver SUD care
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 3/30/2021 (updated 4/5/2024)
This toolkit provides correctional administrators and health care providers the information necessary to plan and implement MAT programs within jails and prisons.
Posted 5/17/2021 (updated 4/10/2024)
FAQs About the New Buprenorphine Practice Guidelines
Buprenorphine Quick Start Guide
Buprenorphine Waiver Notification